Pragya Kaul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pragya Kaul has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Diptatanu Das
Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, Illinois, USA
2 shared publications Manas Pratim Chakraborty
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur campus, Mohanpur, India
2 shared publications- Rahul Das
Indian Institute of Science Education and Research, Kolkata
2 shared publications Soumi Bhattacharyya
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur campus, Mohanpur, India
2 shared publicationsAnnette Artz
Max Planck Institute for Molecular Biomedicine, Münster, Germany
1 shared publication- Astrid Fee Nottebaum
Department of Vascular Cell Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (7) , 2210-2238
Plakoglobin transmits tension across VE-cadherin for vascular leak formation and leukocyte diapedesis
VE-cadherin controls endothelial junction integrity, and thereby inflammation-induced vascular permeability and leukocyte extravasation. The adhesive function of VE-cadherin is influenced by its binding to β-catenin, which is linked by α-catenin to actin. Plakoglobin can replace β-catenin in such complexes, and both types of complexes co-exist in endothelial cells. Here, we have investigated whether β-catenin and plakoglobin differ in their relevance for controlling endothelial junctions. Based on gene silencing in vitro and conditional endothelium-specific gene inactivation in mice in vivo, we found that both leukocyte diapedesis through endothelium and induction of vascular permeability by inflammatory mediators depend on plakoglobin, but not β-catenin. Mechanistically, we demonstrated that plakoglobin is crucial for the generation of tension across VE-cadherin by transmigrating leukocytes and by inflammatory mediators, whereas β-catenin was dispensable in this context. Transgenic mice expressing a VE-cadherin tension sensor revealed that plakoglobin is essential in vivo for histamine-induced tension across VE-cadherin. Thus, plakoglobin, but not β-catenin, is needed for leukocyte diapedesis, the induction of vascular permeability, and the stimulation of mechanical tension across VE-cadherin.
- 11 March 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (7) , 2210-2238
Open AccessPlakoglobin transmits tension across VE-cadherin for vascular leak formation and leukocyte diapedesis
VE-cadherin controls endothelial junction integrity, and thereby inflammation-induced vascular permeability and leukocyte extravasation. The adhesive function of VE-cadherin is influenced by its binding to β-catenin, which is linked by α-catenin to actin. Plakoglobin can replace β-catenin in such complexes, and both types of complexes co-exist in endothelial cells. Here, we have investigated whether β-catenin and plakoglobin differ in their relevance for controlling endothelial junctions. Based on gene silencing in vitro and conditional endothelium-specific gene inactivation in mice in vivo, we found that both leukocyte diapedesis through endothelium and induction of vascular permeability by inflammatory mediators depend on plakoglobin, but not β-catenin. Mechanistically, we demonstrated that plakoglobin is crucial for the generation of tension across VE-cadherin by transmigrating leukocytes and by inflammatory mediators, whereas β-catenin was dispensable in this context. Transgenic mice expressing a VE-cadherin tension sensor revealed that plakoglobin is essential in vivo for histamine-induced tension across VE-cadherin. Thus, plakoglobin, but not β-catenin, is needed for leukocyte diapedesis, the induction of vascular permeability, and the stimulation of mechanical tension across VE-cadherin.
- Open Access
- 14 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Molecular basis of VEGFR1 autoinhibition at the plasma membrane
Ligand-independent activation of VEGFRs is a hallmark of diabetes and several cancers. Like EGFR, VEGFR2 is activated spontaneously at high receptor concentrations. VEGFR1, on the other hand, remains constitutively inactive in the unligated state, making it an exception among VEGFRs. Ligand stimulation transiently phosphorylates VEGFR1 and induces weak kinase activation in endothelial cells. Recent studies, however, suggest that VEGFR1 signaling is indispensable in regulating various physiological or pathological events. The reason why VEGFR1 is regulated differently from other VEGFRs remains unknown. Here, we elucidate a mechanism of juxtamembrane inhibition that shifts the equilibrium of VEGFR1 towards the inactive state, rendering it an inefficient kinase. The juxtamembrane inhibition of VEGFR1 suppresses its basal phosphorylation even at high receptor concentrations and transiently stabilizes tyrosine phosphorylation after ligand stimulation. We conclude that a subtle imbalance in phosphatase activation or removing juxtamembrane inhibition is sufficient to induce ligand-independent activation of VEGFR1 and sustain tyrosine phosphorylation.
- 14 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessMolecular basis of VEGFR1 autoinhibition at the plasma membrane
Ligand-independent activation of VEGFRs is a hallmark of diabetes and several cancers. Like EGFR, VEGFR2 is activated spontaneously at high receptor concentrations. VEGFR1, on the other hand, remains constitutively inactive in the unligated state, making it an exception among VEGFRs. Ligand stimulation transiently phosphorylates VEGFR1 and induces weak kinase activation in endothelial cells. Recent studies, however, suggest that VEGFR1 signaling is indispensable in regulating various physiological or pathological events. The reason why VEGFR1 is regulated differently from other VEGFRs remains unknown. Here, we elucidate a mechanism of juxtamembrane inhibition that shifts the equilibrium of VEGFR1 towards the inactive state, rendering it an inefficient kinase. The juxtamembrane inhibition of VEGFR1 suppresses its basal phosphorylation even at high receptor concentrations and transiently stabilizes tyrosine phosphorylation after ligand stimulation. We conclude that a subtle imbalance in phosphatase activation or removing juxtamembrane inhibition is sufficient to induce ligand-independent activation of VEGFR1 and sustain tyrosine phosphorylation.
- Open Access
Molecular basis of VEGFR1 autoinhibition at the plasma membrane
Ligand-independent activation of VEGFR is a hallmark in diabetes and several cancers. Like most RTKs, the VEGFR2, the primary VEGF receptor, is activated spontaneously at higher receptor concentrations. An exception is VEGFR1, which remains constitutively inactive in the basal state. Ligand stimulation transiently phosphorylates VEGFR1 and induces weak kinase activation in endothelial cells. Recent studies, however, suggest that VEGFR1 signaling is indispensable in regulating various physiological or pathological events, which is puzzling. Why VEGFR1 is differentially regulated is an open question. Here we elucidate a mechanism of juxtamembrane inhibition that shifts the equilibrium more to the inactive state, rendering VEGFR1 an inefficient kinase. Our data suggest that a combination of tyrosine phosphatase activity and JM inhibition suppress the basal phosphorylation of VEGFR1. We conclude that a subtle imbalance in phosphatase activation or removing juxtamembrane inhibition is sufficient to induce basal activation of VEGFR1 and remodel tyrosine phosphorylation to be sustained.
Open AccessMolecular basis of VEGFR1 autoinhibition at the plasma membrane
Ligand-independent activation of VEGFR is a hallmark in diabetes and several cancers. Like most RTKs, the VEGFR2, the primary VEGF receptor, is activated spontaneously at higher receptor concentrations. An exception is VEGFR1, which remains constitutively inactive in the basal state. Ligand stimulation transiently phosphorylates VEGFR1 and induces weak kinase activation in endothelial cells. Recent studies, however, suggest that VEGFR1 signaling is indispensable in regulating various physiological or pathological events, which is puzzling. Why VEGFR1 is differentially regulated is an open question. Here we elucidate a mechanism of juxtamembrane inhibition that shifts the equilibrium more to the inactive state, rendering VEGFR1 an inefficient kinase. Our data suggest that a combination of tyrosine phosphatase activity and JM inhibition suppress the basal phosphorylation of VEGFR1. We conclude that a subtle imbalance in phosphatase activation or removing juxtamembrane inhibition is sufficient to induce basal activation of VEGFR1 and remodel tyrosine phosphorylation to be sustained.